Lumenis Reports Record Attendance for SLT Symposium at ASCRS Meeting

Yokneam, Israel, May 5, 2005 – Lumenis Ltd. (LUME.PK), a global developer, manufacturer and seller of laser and light-based devices for medical, aesthetic, ophthalmic, dental and veterinary applications, announced today the company achieved record attendance at its symposium on Selective Laser Trabeculoplasty (SLT), during which a panel of glaucoma specialists spoke on the latest advancements in SLT therapy. Lumenis hosted this symposium at the American Society of Cataract and Refractive Surgery (ASCRS) meeting recently held in Washington, DC.

“We are very pleased with the strong and growing interest in SLT as evidenced by the robust sales of our exclusive SLT lasers from this meeting,” commented Lumenis President and CEO Avner Raz, “particularly since glaucoma has not been a major focus for the ASCRS meeting in the past.”  Lumenis’ family of Selecta SLT lasers received FDA clearance in 2001, and represents an installed base of nearly 1000 lasers worldwide.

Glaucoma is the second leading cause of preventable blindness worldwide and a silent disease that often goes untreated before significant damage is done. The use of SLT laser treatment has increased rapidly as it eliminates the need for consistent and repeated medication or therapy, and directly addresses compliance concerns. After an SLT laser treatment, the body’s own mechanism is activated, which lowers internal eye pressure and effectively treats the glaucoma patient.

The continued success of SLT is apparent from clinical study posters presented at the major ophthalmic conference, The Association for Research in Vision and Ophthalmology (ARVO), which was held May 1^st – 5^th in Ft. Lauderdale, Florida.  An unprecedented 14 posters were accepted, where the increased clinical application and utility of SLT in glaucoma management was discussed.


Lumenis is not affiliated with ASCRS or ARVO.

For more information about ASCRS please visit www.ascrs.org.
For more information about ARVO, please visit www.arvo.org.


About Lumenis

Lumenis is a global developer, manufacturer and seller of laser and light-based devices for medical, aesthetic, ophthalmic, dental and veterinary applications. The Company offers a wide range of products along with extensive product support systems including training, education and service. Lumenis invests heavily in research and development to maintain and enhance its leading industry position. The Company holds numerous patents worldwide on its technologies. For more information about Lumenis and its products, log onto www.lumenis.com.


Contact:

Lauri Hanover, CFO
1-866-232-6803
+972-4-959-9122

The statements in this press release that are not historical facts are forward-looking statements that are subject to risks and uncertainties. The Company's actual results could differ materially from those anticipated in the forward looking statements based on a variety of factors, including, among others: uncertainties with respect to market acceptance of the Company's products, the implementation and outcome of its Turnaround Plan, obtaining regulatory approvals for new products or for the sale of existing products in new markets and enforcement of intellectual property rights; risks associated with competition and competitive pricing pressures, economic conditions generally, the Company's international operations and the Company's ability to integrate its operations with those of acquired businesses; the outcome of the Securities and Exchange Commission investigation and several securities class action lawsuits to which the Company is subject and the outcome of the investigation conducted by the Audit Committee; uncertainties relating to the Company’s continuing liquidity; and other risks detailed from time to time in the reports filed by Lumenis with the SEC, including its annual report on Form 10-K and quarterly reports on Form 10-Q.